These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23496399)

  • 1. The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure.
    Clarke PM
    Med J Aust; 2013 Mar; 198(5):260. PubMed ID: 23496399
    [No Abstract]   [Full Text] [Related]  

  • 2. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.
    Simoens SR
    Med J Aust; 2011 Jan; 194(1):52-3; author reply 53-4. PubMed ID: 21449876
    [No Abstract]   [Full Text] [Related]  

  • 3. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.
    Clarke PM; Fitzgerald EM
    Med J Aust; 2010 Jun; 192(11):633-6. PubMed ID: 20528715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encouraging generic use can yield significant savings.
    Zimmerman C
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free statins disrupt pharmacy benefit plans.
    Reinke T
    Manag Care; 2012 Nov; 21(11):19-20. PubMed ID: 23236713
    [No Abstract]   [Full Text] [Related]  

  • 6. Challenges and opportunities for the Pharmaceutical Benefits Scheme.
    Clarke PM
    Med J Aust; 2012 Feb; 196(3):153-4. PubMed ID: 22339510
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin utilisation--recognising the role of the invisible hand.
    Minhas R
    Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
    [No Abstract]   [Full Text] [Related]  

  • 9. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium.
    Fraeyman J; Van Hal G; Godman B; Beutels P
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):141-51. PubMed ID: 23402454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of statins' utilization at Ramathobodi Hospital, 2005 to 2007.
    Pattanaprateep O; Pongcharoensuk P; Suvanakoot P; Kaojarern S
    J Med Assoc Thai; 2010 Oct; 93(10):1223-31. PubMed ID: 20973328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching statins: cost of simvastatin is overestimated.
    Ashcroft JS
    BMJ; 2006 Jun; 332(7556):1512. PubMed ID: 16793831
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of reference-pricing systems in Europe: a literature review and case studies.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):729-37. PubMed ID: 22098289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
    Brun J; Ohlsson-Onerud A; Sörensen N
    Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
    [No Abstract]   [Full Text] [Related]  

  • 15. Atherosclerosis patents: clues to the next drug generation.
    Suckling KE
    Biotechnology (N Y); 1994 Dec; 12(13):1379-80. PubMed ID: 7765570
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.
    Godman B; Burkhardt T; Bucsics A; Wettermark B; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):475-84. PubMed ID: 19817531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zero copayment for generic statins could save billions.
    Manag Care; 2013 Mar; 22(3):44. PubMed ID: 23610806
    [No Abstract]   [Full Text] [Related]  

  • 18. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of generic reference pricing interventions in the statin market.
    Puig-Junoy J
    Health Policy; 2007 Nov; 84(1):14-29. PubMed ID: 17368619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.
    Abuelkhair M; Abdu S; Godman B; Fahmy S; Malmström RE; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):115-24. PubMed ID: 22280201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.